2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-175675
    P2Y1 antagonist 4
    P2Y1 antagonist 4 is a selective P2Y1 receptor antagonist with excellent blood-brain barrier (BBB) penetration. P2Y1 antagonist 4 inhibits P2Y1 receptor-mediated cytosolic Ca2+ increase (IC50 = 1.95 μM) and platelet aggregation (IC50 = 3.24 μM) induced by ADP in rabbit washed platelets. P2Y1 antagonist 4 significantly upregulates the level of nuclear Nrf2 protein in H2O2-treated HT22 cells. P2Y1 antagonist 4 reduces myocardial infarct size in a mouse acute myocardial infarction (MI) model. P2Y1 antagonist 4 can be used for the study of ischemic stroke and myocardial infarction.
    P2Y1 antagonist 4
  • HY-175875
    HRZ-01-082-5 3090685-19-8
    HRZ-01-082-5 is an analog of Glutarimide (HY-I0466). HRZ-01-082-5 is a dual-functional molecular glue degrader of SALL4 and OSR1 with a DC50 4.8  nM for OSR1. HRZ-01-082-5 significantly induced SALL4 and OSR1 degradation through CRBN. HRZ-01-082-5 can be used for heart and urogenital development, as well as cancers research.
    HRZ-01-082-5
  • HY-176019
    Methylcarbamyl PAF C-8 98%
    Methylcarbamyl PAF C-8 is resistant to the degradation function of platelet-activating factor acetylhydrolase (PAF-AH). It has a half-life of more than 100 minutes in platelet-poor plasma and possesses the activity of inducing platelet aggregation. In NRK-49 cells overexpressing the PAF receptor, Methylcarbamyl PAF C-8 can induce the expression of c-myc and c-fos, and activate mitogen-activated protein kinase (MAPK). Additionally, Methylcarbamyl PAF C-8 can induce cell cycle arrest in the G1 phase. Methylcarbamyl PAF C-8 holds promise for research in the fields of cardiovascular diseases and anti-cancer therapy.
    Methylcarbamyl PAF C-8
  • HY-176021
    U-44069 serinol amide 98%
    U-44069 serinol amide is a derivative of U-44069 (HY-121825). U-44069 serinol amide is a stable analog of the endoperoxide prostaglandin H2 (HY-136500). U-44069 serinol amide is a vasoconstrictor that can induce preglomerular Ca2+ influx.
    U-44069 serinol amide
  • HY-176022
    U-46619 serinol amide 98%
    U-46619 serinol amide is a derivative of U-46619 (HY-108566). U-46619 serinol amide is a stable analog of Thromboxane A2 (HY-113350) (TXA2). U-46619 serinol amide is a potent TXA2 agonist that can induce platelet shape change and aggregation.
    U-46619 serinol amide
  • HY-176041
    Troponin modulator 1 1448792-38-8 98%
    Troponin modulator 1 (compound 7) modulates the mutant cardiac muscle thin filament function. Troponin modulator 1 enhances Ca2+ sensitivity by phosphorylation with an EC50 of 67 μM .
    Troponin modulator 1
  • HY-176060
    Platelet aggregation-IN-3 1029802-21-8 98%
    Platelet aggregation-IN-3 (Compound 5) is a ligand for H2 histamine receptors, α2(A,C)-adrenergic receptors (α2-AR), and 5-HT2(B,C) serotonin receptors. Platelet aggregation-IN-3 can inhibit platelet aggregation induced by ADP and collagen and can also modulate tumour cell-induced platelet aggregation (TCIPA). Platelet aggregation-IN-3 is promising for research of antiplatelet therapy in cardiovascular diseases and the prevention of cancer-related thrombosis and tumour metastasis.
    Platelet aggregation-IN-3
  • HY-176143
    P2Y1/P2Y6 antagonist 1 98%
    P2Y1/P2Y6 antagonist 1 (Compound 3h) is an indolesulfonylhydrazide derivative. P2Y1/P2Y6 antagonist 1 is an orally active tP2Y1 and rP2Y6 antagonist (IC50 of 9.72 and 1.89 μM, respectively). P2Y1/P2Y6 antagonist 1 can be used in the study of neurological diseases, inflammation, cardiovascular diseases and cancer.
    P2Y1/P2Y6 antagonist 1
  • HY-176215
    RXFP1 receptor agonist-10 2924450-63-3
    RXFP1 receptor agonist-10 (Compound 188) is a RXFP1 receptor agonist (EC50: 0.5 nM). RXFP1 receptor agonist-10 can be used for research of heart failure.
    RXFP1 receptor agonist-10
  • HY-17621S
    Sparsentan-d5 1801597-09-0 98%
    Sparsentan-d5 is deuterium labeled Sparsentan. Sparsentan (RE-021) is a highly potent dual angiotensin II and endothelin A receptor antagonist with Kis of 0.8 and 9.3 nM, respectively.
    Sparsentan-d5
  • HY-176235
    PDE5-IN-14
    PDE5-IN-14 (Compound 14a) is a brain-penetrant competitive phosphodiesterase 5 (PDE5) inhibitor (IC50=16.11 nM). PDE5-IN-14 is promising for research of Alzheimer’s disease (AD), cancer and cardiovascular diseases.
    PDE5-IN-14
  • HY-176241
    DC-174
    DC-174 is an orally active inhibitor of snake venom metalloproteinases (SVMP) with a broad spectrum of inhibitory activity against a variety of snake venom SVMPs. DC-174 acts directly on the active site of SVMPs via zinc-binding groups, inhibiting their enzymatic activity and procoagulant toxicity. DC-174 can significantly prolong the survival time of mice attacked by snake venom. DC-174 can be used in the study of first aid for snake bites.
    DC-174
  • HY-176267
    AH001 1456769-95-1 98%
    AH001 is a orally active RhoA inhibitor, which binds a cryptic pocket proximate to GDP within RhoA with a KD of 73.16 nM. AH001 interacts with GDP, stabilizing RhoA’s interaction with its endogenous inhibitor, RhoGDIα. AH001 reduces the downstream MRTFA nuclear translocation and downregulates fibrosis/hypertrophy proteins. AH001 mitigates myocardial remodeling in multiple HF animal models, and in the 3D myocardial tissue model. AH001 exerts its cardioprotective effects through the RhoA-RhoGDIα axis, effectively inhibiting downstream RhoA activation signaling.
    AH001
  • HY-176333
    Nebivolol O-β-D-glucuronide 98%
    Nebivolol O-β-D-glucuronide is a derivative of Nebivolol (HY-B0203). Nebivolol is an orally active beta receptor blocker and has the high beta(1)-receptor affinity. Nebivolol has direct vasodilator properties and adrenergic blocking characteristics. Nebivolol can be used for the research of kinds of diseases such as hypertension, coronary artery disease, congestive heart failure and ischemic heart disease.
    Nebivolol O-β-D-glucuronide
  • HY-176480
    CYP11B2-IN-3 3072732-90-9
    CYP11B2-IN-3 (compound 32) is an orally active and selective CYP11B2 inhibitor with IC50 values of 12.92 nM and 2341 nM for CYP11B2 and CYP11B1, respectively. CYP11B2-IN-3 can be used for study of hypertension.
    CYP11B2-IN-3
  • HY-176493
    GLP-1R agonist 33 2428641-93-2
    GLP-1R agonist 33 (Compound 224) is a GLP-1 receptor agonist. GLP-1R agonist 33 has the potential to study diabetes, obesity and non-alcoholic fatty liver disease (NAFLD).
    GLP-1R agonist 33
  • HY-176504
    Adenosine receptor agonist 2 2789709-35-7
    Adenosine receptor agonist 2 (Compound 10) is an adenosine A2B receptor (A2BR) agonist with an EC50 of 0.38 nM. Adenosine receptor agonist 2 significantly inhibits the accumulation of cAMP and calcium. Adenosine receptor agonist 2 can be used for cardioprotection research.
    Adenosine receptor agonist 2
  • HY-176543
    Dityramine 4542-40-9 98%
    Dityramine (Bityramine) is an hypertensive agent.
    Dityramine
  • HY-176714
    VUF26034
    VUF26034 (Compound 12b) is a photoresponsive ligand for the human β2-adrenergic receptor (β2-AR.
    VUF26034
  • HY-176779
    Guanidino ethyl disulfide 1072-13-5
    Guanidino ethyl disulfide (GED) (Compound 23) is a NO Synthase (NOS) inhibitor with EC50s of 110, 630 and 180  μM for iNOS, eNOS and bNOS, respectivly. Guanidino ethyl disulfide effectively inhibits nitrite production in J774.2 macrophages. Guanidino ethyl disulfide can be used for circulatory shock, inflammation and neurological diseases research.
    Guanidino ethyl disulfide
Cat. No. Product Name / Synonyms Application Reactivity